Is ATOS or AUPH more undervalued in 2026?

CirclFi compares Atossa Therapeutics, Inc. (ATOS) and Aurinia Pharmaceuticals Inc (AUPH) using 13 institutional-grade valuation models. ATOS has a Quality of Company score of 4.5/10 while AUPH scores 9.9/10.

Which is a better buy — ATOS or AUPH?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ATOS and AUPH valuations compare?

ATOS at $5.19 and AUPH at $15.35 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ATOS vs AUPH Valuation Comparison 2026 — Intrinsic Value Analysis

ATOS

Biotechnology

Atossa Therapeutics, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$5.19

Last close

Models

7/13

Active

AUPH

Biotechnology

Aurinia Pharmaceuticals Inc

Quality

9.9

out of 10

Value Trap

SAFE

Price

$15.35

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	ATOS Fair Value	ATOS Upside	AUPH Fair Value	AUPH Upside
Bayesian DCF	Intrinsic	$3.40	-34.4%	$15.99	+4.1%
Earnings Power Value	Intrinsic	—	—	$6.74	-56.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.52	-90.2%	$17.24	+12.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATOS vs AUPH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATOS vs AUPH — Which Stock Is More Undervalued?

AUPH scores higher with a 9.9/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Atossa Therapeutics, Inc. (ATOS) and Aurinia Pharmaceuticals Inc (AUPH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATOS currently trades at $5.19 with a QOC of 4.5/10, while AUPH trades at $15.35 with a QOC of 9.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).